Anova and Mary Crowley Cancer Research Announce a Partnership to Bring New Treatments to Cancer Patients in Need

On September 22, 2022 Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS technology platform, and the industry’s first collaborative ‘learning system’, reported a partnership with the Mary Crowley Cancer Research (Mary Crowley) to establish and support a technology enabled approach to extend early Phase clinical trials to cancer patients in the Southern and Southwestern United States (Press release, Anova Enterprises, SEP 22, 2022, View Source [SID1234621371]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mary Crowley is a nonprofit cancer research center of excellence that has been delivering the highest quality research for more than 25 years. Their disciplined approach to conducting innovative clinical trials brings hope to cancer patients today while advancing development of treatment for patients in the future. In partnership, Anova and Mary Crowley are accelerating that work.

"Mary Crowley has built a reputation of delivering the highest quality research. We are a leading provider of complex oncology clinical trials in Texas because of the partnerships we serve and our dedicated and patient centric focus to care," said Jon Friedenberg, CEO at Mary Crowley. "Our work with Anova will expand those relationships and enable further growth in the number of patients we serve."

"More than 75 percent of oncology products in development today targeted to patients whose cancer has one or more genetic drivers," said Chris Beardmore, CEO, Anova. "AnovaOS provides a novel IT infrastructure that enables streamlined matching and enrolment to those targeted therapies no matter where that patient receives care. Its revolutionary. In many cases, Phase I clinical trials must be delivered in a specialty center. Being able to deliver complex study opportunities to patients in real time transforms the way research has been historically accessed."

Research sites and physicians interested in participating in this program should register their profile at www.anovaevidence.com. To find out more contact Wubet Redda, Clinical Trial Project Lead at [email protected]